A pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC)
Latest Information Update: 12 Dec 2025
At a glance
- Drugs Aglatimagene besadenovec (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
Most Recent Events
- 12 Dec 2025 New trial record
- 13 Nov 2025 According to Candel Therapeutics media release, company plans to initiate the trial in Q2 2026.